Continuing Education and Professional Development

Big 4 Cancer Conference:
Gynecologic Oncology, Special Populations, Melanoma and Leukemia/Lymphoma

September 22-23, 2017
Holiday Inn World's Fair Park
Knoxville, Tennessee

Register Now

Agenda

Course Overview

The burden of cancer on our population is expected to rise sharply over the next 20 years.  Overall the number of cancer cases is expected to increase by 20% in between 2010 and 2020, with increases largely reflecting an aging population. By 2030, approximately 70% of all cancers will be diagnosed in older adults, and 28% of all cancers will be diagnosed in minorities. As examples, Leukemia is expected to increase by 2% per year.  Ovarian cancer is the 5th leading cause of death in women and the most common gynecologic cause of death. Melanoma is increasing in incidence by at least 2% per year for those over 50 years of age.  

Additionally, the disparities based on socioeconomics, race, education level achieved, and population density continues to contribute to the difference in outcomes for cancer incidence and cancer mortality.  Not only are new therapies needed, but new approaches to address disparities are needed to ensure the greatest impact on reducing the impact of cancer in our communities.   
       
We are moving from the classic model of physician decision-making to shared decision-making and that is going to make a big impact on cancer care. There is growing understanding nationwide of the need for a comprehensive approach to the treatment of cancer patients. Based on data from many scientific trials demonstrating the benefits of multimodal treatments for various cancers, the American College of Surgeons Commission on Cancer (CoC) is strongly encouraging member institutions to provide more emphasis on a cohesive, comprehensive, multidisciplinary approach to each individual cancer patient. A greater commitment on clinical trial accrual is also encouraged, and this is best coordinated via comprehensive cancer tumor board conferences.

The timing of this meeting in the fall allows for the latest findings in clinical cancer research from major oncology conferences to be presented and discussed. This educational activity also meets a unique need for East Tennessee to provide a group of networked and collaborating practitioners to discuss the most recent developments in oncology care in the context of local treatment approaches and patient populations.

Target Audience

Healthcare professionals practicing in:

• Dermatology

• General Surgery

• Gynecologic Oncology

• Hematology/Oncology

• Medical Oncology

• Pathology

• Pharmacy

• Primary Care

• Public Health

• Radiation Oncology

• Surgical Oncology

Course Objectives

At the conclusion of this program, the participant should be able to

• Formulate new therapeutic options for the treatment of melanoma, gynecologic malignancies, and leukemia/lymphoma consistent with NCCN guidelines
• Evaluate current issues and trends in melanoma, gynecologic malignancies, and leukemia/lymphoma that include NCCN guidelines
• Describe recent updates and current controversies in the multidisciplinary management of patients with melanoma, gynecologic malignancies, and leukemia/lymphoma
• Identify creative strategies for collaboration with primary care professionals on overall coordination of patients' cancer care
• Identify opportunities to influence health care disparities through collaboration, educational outreach, and creating unique treatment paradigms

Registration Fees

Fees include all program sessions, continental breakfast, breaks, lunch on Friday, parking at the Holiday Inn, and access to online program materials.